✦ LIBER ✦

Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-α blocking agents: two cases

✍ Scribed by S Lourari; S Prey; C Livideanu; B Jamard; L Lamant; A Cantagrel; C Paul

Book ID: 111095841
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 480 KB
Volume: 23
Category: Article
ISSN: 0926-9959
DOI: 10.1111/j.1468-3083.2008.03074.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Preferential decrease in IgG4 anti-citru

Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis

✍ Bos, W H; Bartelds, G M; Vis, M; van der Horst, A R; Wolbink, G J; van de Stadt, 📂 Article 📅 2008 🏛 BMJ Publishing Group 🌐 English ⚖ 268 KB

Treatment with monoclonal anti–tumor nec

Treatment with monoclonal anti–tumor necrosis factor α antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis

✍ Madelon M. Maurice; Wiebo L. Van Der Graaff; Angela Leow; Ferdinand C. Breedveld 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB 👁 1 views

Regression of subacute cutaneous lupus e

Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor α–blocking agent: Comment on the article by Pisetsky and the letter from Aringer et al

✍ Bruno Fautrel; Violaine Foltz; Camille Frances; Pierre Bourgeois; Sylvie Rozenbe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 700 KB

Assessment of antibodies to double-stran

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trials

✍ P. J. Charles; R. J. T. Smeenk; J. De Jong; M. Feldmann; R. N. Maini 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 2 views

Objective. To compare the incidence of antidouble-stranded DNA (anti-dsDNA) antibodies in rheumatoid arthritis (RA) patients receiving either single or multiple doses of a chimeric anti-tumor necrosis factor ␣ (anti-TNF␣) antibody or placebo infusions, with or without methotrexate, in open-label, ra